130 related articles for article (PubMed ID: 36808891)
1. A Phase 1 Study to Evaluate Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of Savolitinib in Healthy Male Volunteers.
Miah K; Vishwanathan K; Scarfe G; Li Y; Hara I; Cantarini M; Argue J; Menakuru SR
Clin Pharmacol Drug Dev; 2023 Apr; 12(4):424-435. PubMed ID: 36808891
[TBL] [Abstract][Full Text] [Related]
2. Effect of food on the single-dose pharmacokinetics and tolerability of savolitinib in Chinese healthy volunteers.
Ding Q; Ou M; Zhu H; Wang Y; Jia J; Sai Y; Chen Q; Wang J
Fundam Clin Pharmacol; 2022 Feb; 36(1):210-217. PubMed ID: 34022080
[TBL] [Abstract][Full Text] [Related]
3. Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers.
Johne A; Scheible H; Becker A; van Lier JJ; Wolna P; Meyring M
Invest New Drugs; 2020 Oct; 38(5):1507-1519. PubMed ID: 32221754
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects.
Abel S; Russell D; Whitlock LA; Ridgway CE; Nedderman AN; Walker DK
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):60-7. PubMed ID: 18333867
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and ADME Characterization of Intravenous and Oral [
Zamek-Gliszczynski MJ; Kenworthy D; Bershas DA; Sanghvi M; Pereira AI; Mudunuru J; Crossman L; Pirhalla JL; Thorpe KM; Dennison JMTJ; McLaughlin MM; Allinder M; Swift B; O'Connor-Semmes RL; Young GC
Drug Metab Dispos; 2021 Dec; 49(12):1109-1117. PubMed ID: 34625435
[TBL] [Abstract][Full Text] [Related]
6. Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants.
Ucpinar S; Smith PF; Long L; Li F; Yan H; Wadhwa J; Chu KA; Shu J; Nunn P; Li M
Clin Transl Sci; 2023 Jul; 16(7):1210-1219. PubMed ID: 37060187
[TBL] [Abstract][Full Text] [Related]
7. A double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [
Guerini E; Schadt S; Greig G; Haas R; Husser C; Zell M; Funk C; Hartung T; Gloge A; Mallalieu NL
Xenobiotica; 2017 Feb; 47(2):144-153. PubMed ID: 27123695
[TBL] [Abstract][Full Text] [Related]
8. The Absolute Bioavailability and Absorption, Metabolism, and Excretion of Ipatasertib, a Potent and Highly Selective Protein Kinase B (Akt) Inhibitor.
Takahashi RH; Malhi V; Liederer BM; Cho S; Deng Y; Dean B; Nugteren J; Yost E; Al-Sayah MA; Sane R; Kshirsagar S; Ma S; Musib L
Drug Metab Dispos; 2023 Oct; 51(10):1332-1341. PubMed ID: 37524543
[TBL] [Abstract][Full Text] [Related]
9. Parent and Metabolite Concentration-QT Modeling to Evaluate QT-Interval Prolongation at Savolitinib Therapeutic Doses.
Schalkwijk S; Sahota T; Verheijen RB; Harmer AR; Ahmed GF
AAPS J; 2021 Mar; 23(3):46. PubMed ID: 33733338
[TBL] [Abstract][Full Text] [Related]
10. Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers.
O'Donnell J; Lawrence K; Vishwanathan K; Hosagrahara V; Mueller JP
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373802
[TBL] [Abstract][Full Text] [Related]
11. Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C.
Yoh K; Hirashima T; Saka H; Kurata T; Ohe Y; Hida T; Mellemgaard A; Verheijen RB; Ou X; Ahmed GF; Hayama M; Sugibayashi K; Oxnard GR
Target Oncol; 2021 May; 16(3):339-355. PubMed ID: 33939068
[TBL] [Abstract][Full Text] [Related]
12. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers.
Martin PD; Warwick MJ; Dane AL; Hill SJ; Giles PB; Phillips PJ; Lenz E
Clin Ther; 2003 Nov; 25(11):2822-35. PubMed ID: 14693307
[TBL] [Abstract][Full Text] [Related]
13. The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [
Burkard U; Desch M; Shatillo Y; Wunderlich G; Mack SR; Schlecker C; Teitelbaum AM; Liu P; Chan TS
Clin Drug Investig; 2022 Jan; 42(1):87-99. PubMed ID: 34936055
[TBL] [Abstract][Full Text] [Related]
14. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans.
Schwab D; Portron A; Backholer Z; Lausecker B; Kawashima K
Clin Pharmacokinet; 2013 Jun; 52(6):463-73. PubMed ID: 23494983
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of Velsecorat Using an Intravenous Microtracer Combined with an Inhaled Dose in Healthy Subjects.
Holmberg AA; Weidolf L; Necander S; Bold P; Sidhu S; Pelay-Gimeno M; de Ligt RAF; Verheij ER; Jauhiainen A; Psallidas I; Wählby Hamrén U; Prothon S
Drug Metab Dispos; 2022 Feb; 50(2):150-157. PubMed ID: 34853068
[TBL] [Abstract][Full Text] [Related]
16. First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity.
Gan HK; Millward M; Hua Y; Qi C; Sai Y; Su W; Wang J; Zhang L; Frigault MM; Morgan S; Yang L; Lickliter JD
Clin Cancer Res; 2019 Aug; 25(16):4924-4932. PubMed ID: 30952639
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Sequist LV; Han JY; Ahn MJ; Cho BC; Yu H; Kim SW; Yang JC; Lee JS; Su WC; Kowalski D; Orlov S; Cantarini M; Verheijen RB; Mellemgaard A; Ottesen L; Frewer P; Ou X; Oxnard G
Lancet Oncol; 2020 Mar; 21(3):373-386. PubMed ID: 32027846
[TBL] [Abstract][Full Text] [Related]
18. Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite.
Glaenzel U; Jin Y; Hansen R; Schroer K; Rahmanzadeh G; Pfaar U; Jaap van Lier J; Borell H; Meissner A; Camenisch G; Zhao S
Drug Metab Dispos; 2020 Oct; 48(10):873-885. PubMed ID: 32665418
[TBL] [Abstract][Full Text] [Related]
19. Revefenacin Absorption, Metabolism, and Excretion in Healthy Subjects and Pharmacological Activity of Its Major Metabolite.
Bourdet DL; Yeola S; Hegde SS; Colson PJ; Barnes CN; Borin MT
Drug Metab Dispos; 2020 Dec; 48(12):1312-1320. PubMed ID: 32978223
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the absolute bioavailability, mass balance, metabolism, and excretion of the cholesterol 24-hydroxylase inhibitor soticlestat in healthy volunteers.
Yin W; Ballard TE; Zhu SX; Hsiao S; Chen H; Li Y; Chowdhury SK; Stevenson A; Hui T; Hunt A; Asgharnejad M; Han S
Br J Clin Pharmacol; 2024 Feb; 90(2):516-527. PubMed ID: 37771051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
